BFC Planning’s Silexion Therapeutics SLXN Stock Holding History
Bought
Maintained
Sold
Other funds holding SLXN
WAM
PK
BFC Planning's SLXN Position: Q3 2026 in Review
BFC Planning held its Silexion Therapeutics (SLXN) position steady in Q3 2026 at 6 shares worth $37. The position accounts for ﹤0.01% of the portfolio, ranked #3426.
BFC Planning first reported a position in SLXN in Q2 2026 and has held it in 2 quarters since. The position peaked at $339 in Q2 2026. 7 funds tracked by Wall St. Rank hold SLXN as of Q3 2026.
- BFC Planning held 6 shares of Silexion Therapeutics worth $37 as of Q3 2026.
- BFC Planning left its Silexion Therapeutics share count unchanged in Q3 2026.
- Silexion Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3426 holding.
- BFC Planning first reported a position in Silexion Therapeutics in Q2 2026 and has held it in 2 quarters since.
- BFC Planning's Silexion Therapeutics position peaked at $339 in Q2 2026.
- 7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.